By Lauran Neergaard

Hospital workers begin unloading precious frozen vials of COVID-19 vaccine Monday, with the first vaccinations against a scourge that has killed nearly 300,000 Americans expected later in the day.

“It feels like the cavalry is arriving,” Robert C. Garrett, CEO of Hackensack Meridian Health, said as New Jersey’s largest health network awaited delivery.

Shots made by Pfizer Inc. and its German partner BioNTech are the first authorized for emergency use by the Food and Drug Administration -- beginning what will become the largest vaccination campaign in U.S. history. Several other countries also have OK'd the vaccine, including the U.K., which started vaccinating last week.

For health care workers who, along with nursing home residents, will be first in line for vaccination, hope is tempered by grief and the sheer exhaustion of months spent battling a coronavirus that still is surging in the U.S. and around the world.

“This is mile 24 of a marathon. People are fatigued. But we also recognize that this end is in sight,” said Dr. Chris Dale of Swedish Health Services in Seattle.

Packed in dry ice to stay at ultra-frozen temperaturesthe first of nearly 3 million doses being shipped in staggered batches this week made their way by truck and by plane around the country Sunday from Pfizer’s Kalamazoo, Michigan, factory. Once they arrive at distribution centers, each state directs where the doses go next.

Some hospitals across the country spent the weekend tracking their packages, refreshing FedEx and UPS websites for clues.

More of the Pfizer-BioNTech vaccine will arrive each week. And later this week, the FDA will decide whether to green light the world’s second rigorously studied COVID-19 vaccine, made by Moderna Inc.

Now the hurdle is to rapidly get vaccine into the arms of millions, not just doctors and nurses but other at-risk health workers such as janitors and food handlers — and then deliver a second dose three weeks later.

“We’re also in the middle of a surge, and it’s the holidays, and our health care workers have been working at an extraordinary pace,” said Sue Mashni, chief pharmacy officer at Mount Sinai Health System in New York City.

Plus, the shots can cause temporary fever, fatigue and aches as they rev up people's immune systems, forcing hospitals to stagger employee vaccinations.

A wary public will be watching closely to see whether health workers embrace vaccination. Just half of Americans say they want to get vaccinated, while about a quarter don’t and the rest are unsure, according to a recent poll by The Associated Press-NORC Center for Public Health Research.

The FDA, considered the world’s most strict medical regulator, said the Pfizer-BioNTech vaccine appears safe and strongly protective -- and laid out the data behind it in a daylong public meeting last week for scientists and consumers alike to see.

“Please people, when you look back in a year and you say to yourself, ‘Did I do the right thing?’ I hope you’ll be able to say, ‘Yes, because I looked at the evidence,’” Dr. Francis Collins, director of the National Institutes of Health, said Sunday on NBC’s Meet the Press. “People are dying right now. How could you possibly say, ‘Let’s wait and see.’”

Still, emergency use means the vaccine was cleared for widespread use before a final study in nearly 44,000 people is complete -- and that research is continuing to try to answer additional questions. While effective against COVID-19 illness, it’s not yet clear if vaccination will stop the symptomless spread that accounts for half of all cases.

The shots still must be studied in children, and during pregnancy. But the American College of Obstetricians and Gynecologists said late Sunday that vaccination should not be withheld from pregnant women who otherwise would qualify.

While the vaccine was determined to be safe, regulators in the U.K. are investigating several severe allergic reactions. The FDA’s instructions tell providers not to give it to those with a known history of severe allergic reactions to any of its ingredients.

AP journalists Tamara Lush and Kathy Young contributed to this report.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Pillow Customization to Improve Sleep; Bringing Green Hydrogen to Scale
On this episode of Cheddar Innovates: President of The Pillow Bar breaks down how everyone can benefit from a pillow customized to their unique way of sleeping; CEO of H2Pro explains how to bring environmentally friendly hydrogen to scale; Cheddar gets a look at Curiosity Stream's 'Suppressed Science.'
Gardening to Improve Wellbeing; Future of A.I. in Healthcare
On this episode of Cheddar Innovates: Gardenuity CEO breaks down how gardening can improve your wellbeing; Augmedix CEO discusses how this technology is helping doctors fight burnout; Cheddar gets a look at Curiosity Stream's 'Suppressed Science.'
Innovation in Prosthetics; New Drug for Anti-Aging
On this episode of Cheddar Innovates: Atom Limbs CEO breaks down how the Atom Touch prosthetic is different from other prosthetics on the market; CEO & Chief Scientific Officer of MyMD explains how the MYMD-1 is on track to be the first FDA-approved drug to treat aging and age-related diseases; A look at Curiosity Stream's 'The Future of Warfare.'
VR to Train Frontline Workers; Digital Marketplace to End Waste
On this episode of Cheddar Innovates: SkilsVR CEO explains how virtual reality is being used to train frontline workers to handle difficult customers; Rubicon CEO breaks down how technology and sustainability will go hand in hand in the future; Cheddar gets a look at 'Our Infinite Universe.'
UN Report Warns Seawalls Alone Will Not Save Coastal Cities
A UN report is warning that relying on seawalls and other engineering fixes will not be enough to keep communities safe from rising sea levels and climate change consequences. Dr. Steve Rose, a senior research economist at the Electric Power Research Institute, joins Cheddar News to discuss.
Oil Price Crisis Could Lead to Speedier Push Toward Clean Energy Transition
As gas prices surge amid the Russian invasion of Ukraine, other nations could potentially transition faster to using clean energy than previously expected. Philip K. Verleger, a senior fellow at the Niskanen Center, joined Cheddar News to explain how this could be a possibility in the near future. "Part of the reason I think we have this invasion and the tantrum that's being thrown by Russia, terrible tantrum, is because the Russians were trying to slow down the transition," he said. "Ironically they speeded it up."
What Biden's Ban on Russian Oil Imports Could Mean for Growing Energy Costs
As Russia intensifies its war on Ukraine, President Biden announced a ban on oil imported from the aggressor nation. Critics of Russia have said this would be the best way to force Putin to pull back, but curbs on Russian oil exports are expected to send already skyrocketing oil and gas prices even higher, further impacting consumers, businesses, financial markets, and the global economy. Leslie Beyer, CEO of the Energy Workforce and Technology Council, joined Cheddar News' Closing Bell to discuss. "It's certainly going to increase pricing, but it is the right thing to do," she said. "The industry itself has already pulled out of the significant portion of its operations in Russia."
Future of the E-Boating Industry; Making Smart Socks a Reality
On this episode of Cheddar Innovates: Vision Marine Technologies CEO discusses how e-boats will play a role in the fight against the climate crisis; Lasso CEO breaks down how the design behind these compression socks can prevent injuries and improve performance; Cheddar gets a look at Curiosity Stream's 'The Tombs Of Egypt.'
How Omicron Derailed Pfizer Vaccine for Children Under the Age of 5
Vaccine maker Pfizer delayed its COVID shot for kids allegedly due to a lack of data on how it would perform against the omnicron variant, according to the Wall Street Journa. Peter Pitts, professor and founder of the Center for Medicine in the Public Interest and a former FDA associate commissioner, joined Cheddar News Wrap to break down why the authorization can't be rushed. "Going forward, the FDA wants to look at data specifically against omicron, and it looks like that's going to be a three-shot regimen versus two, which was efficient against delta but not omicron because obviously omicron is more infectious," said Pitts.
Load More